Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 39 articles:
HTML format
Text format



Single Articles


    May 2017
  1. SCALICI JM, Arapovic S, Saks EJ, Atkins KA, et al
    Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
    Cancer. 2017;123:977-984.
    PubMed     Text format     Abstract available


    March 2017
  2. SAMIMI G, Minasian LM
    Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30525.
    PubMed     Text format    


    November 2016
  3. RUNGRUANG BJ, Miller A, Krivak TC, Horowitz NS, et al
    What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Cancer. 2016 Nov 16. doi: 10.1002/cncr.30414.
    PubMed     Text format     Abstract available


    July 2016
  4. DRESCHER CW, Beatty JD, Resta R, Andersen MR, et al
    The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.
    Cancer. 2016 Jul 22. doi: 10.1002/cncr.30190.
    PubMed     Text format     Abstract available


    June 2016
  5. GUINDALINI RS, Song A, Fackenthal JD, Olopade OI, et al
    Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
    Cancer. 2016;122:1913-20.
    PubMed     Text format     Abstract available


    May 2016
  6. BRADLEY MC, Black A, Freedman AN, Barron TI, et al
    Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30004.
    PubMed     Text format     Abstract available


    April 2016
  7. PRINTZ C
    BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety.
    Cancer. 2016;122:1149.
    PubMed     Text format    


  8. MATULONIS UA, Harter P, Gourley C, Friedlander M, et al
    Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
    Cancer. 2016 Apr 8. doi: 10.1002/cncr.29995.
    PubMed     Text format     Abstract available


    January 2016
  9. WALSH CS
    The more you look, the more you will find.
    Cancer. 2016;122:14-6.
    PubMed     Text format    


    November 2015
  10. TAN L, Wang W, He G, Kuick RD, et al
    Resveratrol inhibits ovarian tumor growth in an in vivo mouse model.
    Cancer. 2015 Nov 30. doi: 10.1002/cncr.29793.
    PubMed     Text format     Abstract available


  11. NOONAN AM, Bunch KP, Chen JQ, Herrmann MA, et al
    Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
    Cancer. 2015 Nov 13. doi: 10.1002/cncr.29783.
    PubMed     Text format     Abstract available


  12. TJALMA WA
    Staging classification for cancer of the ovary and fallopian tube should include in situ carcinoma.
    Cancer. 2015 Nov 4. doi: 10.1002/cncr.29776.
    PubMed     Text format    


  13. DENNY L
    Reply to staging classification for cancer of the ovary and fallopian tube should include in situ carcinoma.
    Cancer. 2015 Nov 4. doi: 10.1002/cncr.29774.
    PubMed     Text format    


    October 2015
  14. PASHANKAR F, Hale JP, Dang H, Krailo M, et al
    Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative.
    Cancer. 2015 Oct 20. doi: 10.1002/cncr.29732.
    PubMed     Text format     Abstract available


  15. HURTEAU JA, Febbraro T
    Germ cell tumors: Treatment consensus across all age groups through MaGIC [Malignant Germ Cell International Collaborative].
    Cancer. 2015 Oct 20. doi: 10.1002/cncr.29729.
    PubMed     Text format    


  16. VENNIYOOR A
    Beta-blockers in epithelial ovarian cancer.
    Cancer. 2015 Oct 9. doi: 10.1002/cncr.29722.
    PubMed     Text format    


  17. SCHMIDT SA, Schmidt M
    Beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?
    Cancer. 2015 Oct 7. doi: 10.1002/cncr.29721.
    PubMed     Text format    


  18. THAKER PH, Urbauer DL, Sood AK
    Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?
    Cancer. 2015 Oct 7. doi: 10.1002/cncr.29723.
    PubMed     Text format    


  19. SAKAMOTO I, Hirotsu Y, Nakagomi H, Ouchi H, et al
    BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
    Cancer. 2015 Oct 6. doi: 10.1002/cncr.29707.
    PubMed     Text format     Abstract available


    August 2015
  20. BUNCH KP, Annunziata CM
    Are beta-blockers on the therapeutic horizon for ovarian cancer treatment?
    Cancer. 2015 Aug 24. doi: 10.1002/cncr.29394.
    PubMed     Text format    


  21. WATKINS JL, Thaker PH, Nick AM, Ramondetta LM, et al
    Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.
    Cancer. 2015 Aug 24. doi: 10.1002/cncr.29392.
    PubMed     Text format     Abstract available


    July 2015

  22. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK and Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269-275.
    Cancer. 2015;121:2474-2475.
    PubMed     Text format    


    June 2015
  23. DUSKA LR, Kohn EC
    Does one size fit all? The updated ovarian cancer staging: Still a work in progress.
    Cancer. 2015 Jun 25. doi: 10.1002/cncr.29521.
    PubMed     Text format    


  24. PRAT J
    Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum.
    Cancer. 2015 Jun 25. doi: 10.1002/cncr.29524.
    PubMed     Text format     Abstract available


  25. DAVIS LZ, Slavich GM, Thaker PH, Goodheart MJ, et al
    Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer.
    Cancer. 2015 Jun 10. doi: 10.1002/cncr.29516.
    PubMed     Text format     Abstract available


  26. LHEUREUX S, Karakasis K, Kohn EC, Oza AM, et al
    Ovarian cancer treatment: The end of empiricism?
    Cancer. 2015 Jun 10. doi: 10.1002/cncr.29481.
    PubMed     Text format     Abstract available


  27. DANCEY JE
    Assessing benefit in trials: are we making progress in assessing progression in cancer clinical trials?
    Cancer. 2015;121:1728-30.
    PubMed     Text format    


    March 2015
  28. BRAWLEY OW
    Ovarian cancer prevention: Time for primetime?
    Cancer. 2015 Mar 27. doi: 10.1002/cncr.29347.
    PubMed     Text format    


  29. WALKER JL, Powell CB, Chen LM, Carter J, et al
    Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.
    Cancer. 2015 Mar 27. doi: 10.1002/cncr.29321.
    PubMed     Text format     Abstract available


    February 2015
  30. PAUL J
    Targeted survival improvements in clinical trials: are you an absolutist or relativist?
    Cancer. 2015;121:335-8.
    PubMed     Text format    


  31. VILLARREAL-GARZA C, Alvarez-Gomez RM, Perez-Plasencia C, Herrera LA, et al
    Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
    Cancer. 2015;121:372-8.
    PubMed     Text format     Abstract available


    January 2015
  32. PRINTZ C
    Attorneys aim to reform "compassionate use": groups say the regulatory system lags behind scientific advances.
    Cancer. 2015;121:163-4.
    PubMed     Text format    


    December 2014
  33. VAUGHN DJ, Hwang W, Lal P, Rosen MA, et al
    Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
    Cancer. 2014 Dec 18. doi: 10.1002/cncr.29213.
    PubMed     Text format     Abstract available


  34. JAMISON PM, Altekruse SF, Chang JT, Zahn J, et al
    Site-specific factors for cancer of the corpus uteri from SEER registries: collaborative stage data collection system, version 1 and version 2.
    Cancer. 2014;120 Suppl 23:3836-45.
    PubMed     Text format     Abstract available


    September 2014
  35. MERSCH J, Jackson MA, Park M, Nebgen D, et al
    Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
    Cancer. 2014 Sep 15. doi: 10.1002/cncr.29041.
    PubMed     Text format     Abstract available


  36. KONSTANTINOPOULOS PA, Matulonis UA
    POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: Implications for Lynch syndrome testing.
    Cancer. 2014 Sep 15. doi: 10.1002/cncr.29057.
    PubMed     Text format    


  37. BILLINGSLEY CC, Cohn DE, Mutch DG, Stephens JA, et al
    Polymerase varepsilon (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing.
    Cancer. 2014 Sep 15. doi: 10.1002/cncr.29046.
    PubMed     Text format     Abstract available


    July 2014
  38. CO NN, Iglesias D, Celestino J, Kwan SY, et al
    Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.
    Cancer. 2014 Jul 16. doi: 10.1002/cncr.28854.
    PubMed     Text format     Abstract available


    June 2014
  39. MITSUHASHI A, Kiyokawa T, Sato Y, Shozu M, et al
    Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial.
    Cancer. 2014 Jun 10. doi: 10.1002/cncr.28853.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: